Functional Expression of the Recombinant Spike Receptor Binding Domain of SARS-CoV-2 Omicron in the Periplasm of Escherichia coli

A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant known as Omicron has caused a rapid increase in recent global patients with coronavirus infectious disease 2019 (COVID-19). To overcome the COVID-19 Omicron variant, production of a recombinant spike receptor binding domain (...

Full description

Saved in:
Bibliographic Details
Published in:Bioengineering (Basel) 2022-11, Vol.9 (11), p.670
Main Authors: Kim, Woo Sung, Kim, Ji Hyun, Lee, Jisun, Ka, Su Yeon, Chae, Hee Do, Jung, Inji, Jung, Sang Taek
Format: Article
Language:English
Subjects:
ACE2
Amino acids
Angiotensin
Angiotensin-converting enzyme 2
Antibodies
Binding
Bioengineering
Chemical bonds
Coronaviruses
COVID-19
COVID-19 vaccines
Domains
E coli
Enzymes
Escherichia coli
functional expression
Genes
Infectious diseases
Medical research
omicron
Peptidyl-dipeptidase A
Periplasm
Proteins
Receptors
Severe acute respiratory syndrome coronavirus 2
spike receptor binding domain
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant known as Omicron has caused a rapid increase in recent global patients with coronavirus infectious disease 2019 (COVID-19). To overcome the COVID-19 Omicron variant, production of a recombinant spike receptor binding domain (RBD) is vital for developing a subunit vaccine or a neutralizing antibody. Although bacterial expression has many advantages in the production of recombinant proteins, the spike RBD expressed in a bacterial system experiences a folding problem related to disulfide bond formation. In this study, the soluble Omicron RBD was obtained by a disulfide isomerase-assisted periplasmic expression system in Escherichia coli. The Omicron RBD purified from E. coli was very well recognized by anti-SARS-CoV-2 antibodies, sotrovimab (S309), and CR3022, which were previously reported to bind to various SARS-CoV-2 variants. In addition, the kinetic parameters of the purified Omicron RBD upon binding to the human angiotensin-converting enzyme 2 (ACE2) were similar to those of the Omicron RBD produced in the mammalian expression system. These results suggest that an E. coli expression system would be suitable to produce functional and correctly folded spike RBDs of the next emerging SARS-CoV-2 variants quickly and inexpensively.
ISSN:2306-5354
2306-5354
DOI:10.3390/bioengineering9110670